Cells expressing parathyroid hormone 1 receptor and uses thereof
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11103537-B2
Publication Date
2021-08-31
Expiration Date
Abstract
Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.
Core Innovation
The invention provides a method of treating an age-related disorder in a mammalian subject by using pluripotent stem cells that are positive for a parathyroid hormone (PTH) receptor. The method isolates a population of PTH receptor-positive pluripotent stem cells from peripheral blood of the subject, where the isolated cells express parathyroid hormone type 1 receptor (PTH1R) and show defined positivity for CD90 and CD133, defined positive/negative status for CD29, CD34, CD105, and CD106, and negativity for SSEA-3, CD200, and CD45.
The isolated PTH receptor-positive pluripotent stem cells are obtained by contacting the peripheral blood sample with an extracorporeal device and capturing the cells on a porous membrane of the extracorporeal device. Capturing is performed by applying centrifugal force, or by using a porous membrane that comprises an antibody or portion thereof that specifically binds to the PTH receptor-positive pluripotent stem cells, as part of the isolation process.
After isolation, the method transfects the isolated population of PTH receptor-positive pluripotent stem cells with a human telomerase reverse transcriptase (hTERT) gene to generate hTERT transfected PTH receptor-positive pluripotent stem cells. The hTERT transfected cells are then administered in a therapeutically effective amount via a route sufficient to engraft at least a fraction of the hTERT transfected PTH receptor-positive pluripotent stem cells into the tissue to be treated.
The disclosed approach is associated with reducing telomere shortening, increasing cellular self-renewal and lifespan, and reducing fine lines or wrinkles or aging in the subject. The dependent claim set further refines age-related disorder scope and treatment parameters.
Claims Coverage
The provided claim set includes one independent claim, which comprises three core inventive aspects: isolation of PTH receptor-positive pluripotent stem cells using an extracorporeal porous-membrane capture, hTERT transfection of the isolated population, and administration of the resulting cells to engraft in tissue to treat an age-related disorder. The dependent claims refine cell markers, transfection modality, dosing concentration, administration schedule, and porous membrane antibody composition, and add claimed functional outcomes.
Age-related disorder treatment with PTH receptor-positive pluripotent stem cells
A method of treating an age-related disorder in a mammalian subject in need thereof by isolating a population of parathyroid hormone (PTH) receptor-positive pluripotent stem cells from peripheral blood, wherein the isolated population expresses parathyroid hormone type 1 receptor (PTH1R) and has defined positivity and negativity for CD90, CD133, CD29, CD34, CD105, CD106, SSEA-3, CD200, and CD45.
Extracorporeal porous membrane capture of PTH receptor-positive pluripotent stem cells
Isolating the PTH receptor-positive stem cells comprises contacting the peripheral blood sample with an extracorporeal device and capturing the PTH receptor-positive pluripotent stem cells on a porous membrane of the extracorporeal device, wherein capturing comprises applying centrifugal force to the extracorporeal device, or wherein the porous membrane comprises an antibody or portion thereof that specifically binds to the PTH receptor-positive pluripotent stem cells.
hTERT transfection and engraftment for tissue treatment
Transfecting the isolated population with a human telomerase reverse transcriptase (hTERT) gene to generate hTERT transfected PTH receptor-positive pluripotent stem cells, and administering the hTERT transfected PTH receptor-positive pluripotent stem cells to the subject in a therapeutically effective amount via a route sufficient to engraft at least a fraction of the hTERT transfected PTH receptor-positive pluripotent stem cells into the tissue to be treated.
Across the independent claim, the coverage centers on selecting PTH1R-expressing, CD90+ and CD133+ pluripotent stem cells from peripheral blood, capturing them using an extracorporeal device with a porous membrane using centrifugal force and/or antibody-mediated binding, and transfecting with an hTERT gene followed by administering the transfected cells for engraftment in tissue to treat an age-related disorder.
Stated Advantages
Reducing telomere shortening.
Increasing cellular self-renewal and lifespan.
Reducing fine lines or wrinkles or aging in the subject.
Documented Applications
No documented applications found
Interested in licensing this patent?